胃黏膜肠上皮化生严重程度预测胃癌风险:一项前瞻性多中心队列研究(GCEP)
该前瞻性多中心队列研究在新加坡纳入2980例接受筛查胃镜并标准化胃黏膜取样的患者,随访至第3年和第5年,并与国家疾病登记处匹配以发现漏诊的早期胃肿瘤。结果显示肠上皮化生是早期胃肿瘤的显著危险因素(调整HR 5.36),OLGIM III-IV期风险最高(调整HR 20.7),OLGIM II期亦显著(调整HR 7.34)。作者建议按风险分层:高危(OLGIM III-IV)2年内镜监测,中危(OLGIM II)5年监测。
要点
- 肠上皮化生显著增加早期胃肿瘤风险(调整HR 5.36,95%CI 1.51-19.0)。
- OLGIM III-IV期风险最高(调整HR 20.7),推荐2年内镜监测。
- OLGIM II期亦显著风险(调整HR 7.34),推荐5年内镜监测。
核心结论
- 肠上皮化生是早期胃肿瘤的显著危险因素,OLGIM分期越高风险越大。
- 建议对OLGIM III-IV期高危患者2年内镜监测,OLGIM II期中危患者5年监测。
研究设计与样本
- 前瞻性、纵向、多中心研究,在新加坡开展,纳入2980例接受筛查胃镜并标准化胃黏膜取样的患者。
- 随访期间安排第3年和第5年监测胃镜,并与国家疾病登记处匹配以发现漏诊的早期胃肿瘤。
主要发现
- 共21例参与者诊断为早期胃肿瘤。
- 肠上皮化生是早期胃肿瘤的显著危险因素(调整HR 5.36;95%CI 1.51-19.0;p<0.01)。
- 有和无肠上皮化生患者的年龄调整早期胃肿瘤发病率分别为133.9和12.5/10万人年。
- OLGIM III-IV期风险最高(调整HR 20.7;95%CI 5.04-85.6;p<0.01),OLGIM II期亦显著(调整HR 7.34;95%CI 1.60-33.7;p=0.02)。
- 基线OLGIM III-IV期归因的早期胃肿瘤中超过一半(4/7)在2年内发生(范围12.7-44.8个月)。
关键数值与推荐
- OLGIM III-IV期:调整HR 20.7(95%CI 5.04-85.6;p<0.01)。
- OLGIM II期:调整HR 7.34(95%CI 1.60-33.7;p=0.02)。
- 血清三叶因子3在幽门螺杆菌阴性患者中区分OLGIM III-IV期的AUC为0.749。
- 显著吸烟史进一步增加OLGIM II-IV期患者的早期胃肿瘤风险。
临床怎么用
- 对OLGIM III-IV期高危患者建议2年内镜监测。
- 对OLGIM II期中危患者建议5年内镜监测。
- 可考虑检测血清三叶因子3辅助识别幽门螺杆菌阴性的OLGIM III-IV期患者。
- 评估吸烟史以进一步分层OLGIM II-IV期患者的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the incidence of gastric cancer (GC) attributed to gastric intestinal metaplasia (IM), and validate the Operative Link on Gastric Intestinal Metaplasia (OLGIM) for targeted endoscopic surveillance in regions with low-intermediate incidence of GC. METHODS: A prospective, longitudinal and multicentre study was carried out in Singapore. The study participants comprised 2980 patients undergoing screening gastroscopy with standardised gastric mucosal sampling, from January 2004 and December 2010, with scheduled surveillance endoscopies at year 3 and 5. Participants were also matched against the National Registry of Diseases Office for missed diagnoses of early gastric neoplasia (EGN). RESULTS: There were 21 participants diagnosed with EGN. IM was a significant risk factor for EGN (adjusted-HR 5.36; 95% CI 1.51 to 19.0; p<0.01). The age-adjusted EGN incidence rates for patients with and without IM were 133.9 and 12.5 per 100 000 person-years. Participants with OLGIM stages III-IV were at greatest risk (adjusted-HR 20.7; 95% CI 5.04 to 85.6; p<0.01). More than half of the EGNs (n=4/7) attributed to baseline OLGIM III-IV developed within 2 years (range: 12.7-44.8 months). Serum trefoil factor 3 distinguishes (Area Under the Receiver Operating Characteristics 0.749) patients with OLGIM III-IV if they are negative for H. pylori. Participants with OLGIM II were also at significant risk of EGN (adjusted-HR 7.34; 95% CI 1.60 to 33.7; p=0.02). A significant smoking history further increases the risk of EGN among patients with OLGIM stages II-IV. CONCLUSIONS: We suggest a risk-stratified approach and recommend that high-risk patients (OLGIM III-IV) have endoscopic surveillance in 2 years, intermediate-risk patients (OLGIM II) in 5 years.
引用
- Lee JWJ, Zhu F, Srivastava S, et al. Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP). Gut. 2021. PMID: 33975867. doi:10.1136/gutjnl-2021-324057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。